Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis compassionate pricing program in Canada by increasing the yearly income eligibility threshold from $40,000 to $60,000 CAD. This expansion makes Aurora's program the most inclusive medical cannabis pricing plan in Canada, potentially benefiting over half of the country's adult population.

The company has also introduced new medical cannabis products including Aurora | Mediora Minis (Cannatonic CBD Flower), Daily Special | Sativa J's (THC Pre-Rolls), and WMMC | Seasonal Stash Petro Biscuit (THC Flower). Aurora continues to provide resources for seniors, pediatric patients, veterans, and first responders through their medical cannabis program.

Positive

• Increased income eligibility threshold by 50% (from $40,000 to $60,000 CAD)
• Program now accessible to over 50% of Canada's adult population
• Introduction of new medical cannabis products expanding product portfolio
• Continued support for special groups including veterans and seniors

Negative

• None.

Insights

Cannabis Industry Analyst

Aurora expands medical cannabis affordability, potentially reaching 50%+ of Canadian adults and strengthening market leadership.

Aurora Cannabis has made a strategic market expansion move by increasing the income threshold for its compassionate pricing program from $40,000 to $60,000 CAD. This 50% increase in the eligibility threshold significantly widens their addressable market, with the company claiming it now encompasses over half of Canada's adult population.

This initiative represents a calculated approach to patient acquisition and retention in the competitive Canadian medical cannabis landscape. By positioning their program as "the most inclusive medical cannabis pricing plan in Canada," Aurora is leveraging pricing strategy as a competitive differentiator while reinforcing their self-described position as "Canada's Largest Medical Cannabis Company."

The simultaneous launch of three new medical cannabis products across different formats (flower and pre-rolls) and cannabinoid profiles (CBD and THC) demonstrates Aurora's commitment to portfolio expansion alongside price accessibility. This two-pronged approach addresses both affordability barriers and product diversity needs in the medical cannabis segment.

From a market positioning perspective, this initiative aligns with Aurora's broader patient-centered strategy, which includes specialized resources for demographic segments like seniors, pediatric patients, veterans, and first responders. While the exact discount percentage isn't disclosed, the expanded eligibility creates a pathway to potential volume growth, though likely with some margin trade-offs that will need careful management to optimize overall financial performance.

Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program

NASDAQ | TSX: ACB

EDMONTON, AB, June 26, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through AuroraMedical.com.

"As over half of the country's adult population fits within this income threshold, our compassionate pricing program represents the most accessible, inclusive pricing plan to access medical cannabis in Canada," says Geoff Hoover, SVP of Canadian Commercial at Aurora. "We're committed to breaking down barriers to access high quality medical cannabis, and this change empowers more patients to explore different treatment options at pricing they can afford."

The changes to the compassionate pricing program are available alongside new medical cannabis products, including:

• Aurora | Mediora Minis – Cannatonic CBD Flower, Sativa (10mg)
• Daily Special | Sativa J's - THC Pre-Rolls, Sativa (7 x 0.3g)
• WMMC | Seasonal Stash Petro Biscuit – THC Flower, Indica (10mg)

In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit www.auroramedical.com for more information and to connect with the Aurora client care team for further support.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company's expanded compassionate pricing program, and associated benefits for patients.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses,  the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-expands-patient-access-to-medical-cannabis-in-canada-with-extended-compassionate-pricing-program-302491509.html

SOURCE Aurora Cannabis Inc.

FAQ

What changes did Aurora Cannabis (ACB) make to its compassionate pricing program in 2025?

Aurora increased the yearly income eligibility threshold from $40,000 to $60,000 CAD, making it the most inclusive medical cannabis pricing program in Canada.

What new medical cannabis products did Aurora (ACB) introduce in June 2025?

Aurora introduced three new products: Aurora | Mediora Minis (CBD Flower), Daily Special | Sativa J's (THC Pre-Rolls), and WMMC | Seasonal Stash Petro Biscuit (THC Flower).

Who is eligible for Aurora Cannabis's compassionate pricing program?

Patients with yearly income up to $60,000 CAD are eligible, along with special groups including seniors, pediatric patients, veterans, and first responders.

What percentage of Canadian adults are eligible for Aurora's compassionate pricing program?

According to Aurora, over 50% of Canada's adult population falls within the income threshold for the compassionate pricing program.